Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int J Immunopathol Pharmacol ; 26(3): 801-6, 2013.
Article in English | MEDLINE | ID: mdl-24067481

ABSTRACT

Buckwheat allergy is considered a rare food allergy outside of Asia. In Europe, buckwheat has been described mainly as a hidden allergen. Data on the prevalence of buckwheat hypersensitivity in non-Asian countries is very poor. The aim of this multicenter study was to evaluate the prevalence of buckwheat sensitization and its association with other sensitizations among patients referred to allergy clinics in different geographic areas of Italy. All patients referred to 18 Italian allergy clinics from February through April 2011 were included in the study and evaluated for sensitization to buckwheat and other allergens depending on their clinical history. A total of 1,954 patients were included in the study and 61.3 percent of them were atopic. Mean prevalence of buckwheat sensitization was 3.6 percent with significant difference between Northern (4.5 percent), Central (2.2 percent) and Southern (2.8 percent) regions. This is, to our knowledge, the largest epidemiological survey on buckwheat allergy reported outside of Asia. Buckwheat is an emerging allergen in Italy, being more frequently associated to sensitization in Northern regions.


Subject(s)
Allergens , Fagopyrum/adverse effects , Food Hypersensitivity/epidemiology , Adult , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Humans , Italy/epidemiology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Referral and Consultation , Skin Tests , Young Adult
2.
Int J Immunopathol Pharmacol ; 25(3): 671-9, 2012.
Article in English | MEDLINE | ID: mdl-23058017

ABSTRACT

Sublingual immunotherapy with monomeric carbamylated allergoid (LAIS) is an effective and well tolerated treatment of respiratory allergy. The aim of the present study was to correlate the efficacy of two maintenance doses (1000 AU vs 3000 AU) of LAIS with the immunological modulation of allergen-driven Th1, Th2 and T regulatory cytokines produced in vitro by PBMCs, in patients suffering from mite allergic rhinitis. Forty-eight consecutive patients with mite allergic rhinitis were recruited. Patients were randomly assigned to group A (n=24) or group B (n=24), respectively receiving 1000 AU or 3000 AU weekly during one-year maintenance phase. Each patient was evaluated for rhinitis severity (ARIA protocol), and for drug consumption at the time of the inclusion and after 6 and 12 months of treatment. Patients were also asked to report the perceived severity of the disease and the tolerability of the treatment in a visual analogical scale (VAS). Before and at the end of the treatment allergen-driven release of cytokines by PBMCs in vitro was measured. After 1-year treatment, a statistically significant reduction of all clinical parameters was observed in all patients, associated with reduction of IL-4 and increase of INF-γ secreted in vitro by mite-challenged PBMCs. Notably, the group treated with the higher dose showed significantly better clinical and immunological results. The efficacy of LAIS is correlated to the immune modulation in a clear dose-dependent effect.


Subject(s)
Antigens, Dermatophagoides/administration & dosage , Desensitization, Immunologic/methods , Plant Extracts/administration & dosage , Pyroglyphidae/immunology , Rhinitis, Allergic, Perennial/therapy , Administration, Sublingual , Adult , Allergoids , Animals , Antigens, Dermatophagoides/adverse effects , Cells, Cultured , Chi-Square Distribution , Cytokines/metabolism , Desensitization, Immunologic/adverse effects , Dose-Response Relationship, Immunologic , Histamine Antagonists/therapeutic use , Humans , Intradermal Tests , Italy , Plant Extracts/adverse effects , Prospective Studies , Rhinitis, Allergic , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Perennial/immunology , Severity of Illness Index , T-Lymphocytes, Regulatory/immunology , Th1 Cells/immunology , Th2 Cells/immunology , Time Factors , Treatment Outcome
3.
Int J Immunopathol Pharmacol ; 23(1): 193-201, 2010.
Article in English | MEDLINE | ID: mdl-20378005

ABSTRACT

Some patients with nickel (Ni) allergic contact dermatitis suffer from systemic (intestinal or cutaneous) symptoms after ingestion of Ni-rich foods and experience symptoms reduction with low-Ni diet, a condition termed Systemic Ni Allergy Syndrome (SNAS). We aimed at evaluating whether oral administration of low nickel doses improved clinical conditions and modulated immunological aspects of SNAS, without significant side effects. Thirty-six SNAS patients were enrolled. Treatment started after 1-month of low-Ni diet and consisted in an incremental oral NiOH dose phase (0.3ng to 1.5 microg/week) followed by a 12-months maintenance phase (1.5 microg/week). Randomly, twenty-four patients added Ni therapy to low-Ni diet and 12 remained with diet alone. All patients were allowed rescue medications (antihistamines and topical steroids). After 4 months, Ni-rich foods were gradually reintroduced. In vitro allergen-driven IL13, IL5 and IFN-gamma release by peripheral blood mononuclear cells was evaluated before and after treatment. Twenty-three patients receiving NiOH and the 12 control patients completed the study. Evaluation of SNAS clinical severity (by VAS and drug consumption) showed a significant difference in favor of NiOH-treated patients compared to controls. Twenty of 23 patients in the NiOH group and none in the control group tolerated Ni-rich food reintroduction. Release of all studied cytokines in culture supernatants was significantly lower after NiOH treatment. In conclusion NiOH is effective in reducing symptoms and drug consumption in SNAS and is able to modulate inflammatory parameters.


Subject(s)
Cytokines/biosynthesis , Desensitization, Immunologic , Hypersensitivity/therapy , Nickel/adverse effects , Th1 Cells/immunology , Th2 Cells/immunology , Administration, Oral , Adult , Aged , Double-Blind Method , Female , Humans , Hypersensitivity/immunology , Male , Middle Aged , Syndrome
4.
Article in English | MEDLINE | ID: mdl-20232775

ABSTRACT

BACKGROUND: Hymenoptera venom immunotherapy (VIT) is a safe and effective approach to insect sting allergy. However, after discontinuation, relapses can occur in some patients, especially those with a high occupational risk, and they may need to prolong VIT indefinitely. In order to improve adherence, we propose extending the interval between injections of maintenance VIT (MVIT). OBJECTIVE: To evaluate the safety, efficacy, and patient acceptance of a 3-month interval between MVIT injections in a group of Hymenoptera-allergic patients who are occupationally exposed to insect stings. PATIENTS AND METHODS: We included 72 patients with severe systemic reactions to Hymenoptera stings. MVIT was administered for 4 years at intervals increasing up to 3 months and then continued for a further 2 years. Patients were informed of the risk of relapse after discontinuation and of the need for indefinite treatment at 3-month intervals. RESULTS: During the 3-month interval maintenance phase, only 235 local reactions (17.8%) were observed in 17 patients. Sixty patients experienced 125 field re-stings and only 1 experienced a systemic reaction with generalized urticaria. CONCLUSIONS: The study confirms that the conventional MVIT interval of 4 to 6 weeks can be extended to 3 months in most patients with no adverse events, while maintaining safety and efficacy, improving adherence, and guaranteeing safe continuation of professional activity.


Subject(s)
Bee Venoms/administration & dosage , Desensitization, Immunologic/methods , Hypersensitivity/therapy , Insect Bites and Stings/therapy , Wasp Venoms/administration & dosage , Adolescent , Adult , Aged , Bee Venoms/immunology , Desensitization, Immunologic/adverse effects , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Patient Compliance , Wasp Venoms/immunology
5.
Arch Gerontol Geriatr ; 49 Suppl 1: 221-6, 2009.
Article in English | MEDLINE | ID: mdl-19836636

ABSTRACT

Fas and Fas ligand (FasL), members of the tumor necrosis factor (TNF) and TNF-receptor (TNFR) families of molecules, are involved in apoptosis. They are expressed in membrane-associated as well as soluble forms (sFas, and sFasL). Apoptotic defects underlie some models of autoimmune diseases, and they have been proposed in the pathogenesis of systemic lupus erythematosus (SLE) a prototypic autoimmune disorder. We measured the serum levels of sFas and sFasL in a series of well characterized SLE patients and devised an index of the two forms which resulted to be associated with age, indicating that apoptosis resistance is modulated during aging, thus explaining the conflicting observations made in previous studies.


Subject(s)
Aging/blood , Fas Ligand Protein/blood , Lupus Erythematosus, Systemic/blood , fas Receptor/blood , Adolescent , Adult , Apoptosis/physiology , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Severity of Illness Index , Young Adult
6.
Int J Immunopathol Pharmacol ; 20(2 Suppl 2): 15-22, 2007.
Article in English | MEDLINE | ID: mdl-17903351

ABSTRACT

Immunotoxicity of metal compounds is an issue of great importance due to the recent industrial application of metals with unknown toxicity on the immune system and the discovery of metal intermediary compounds not sufficiently studied yet. In this report we show results of our study on the immunotoxicity of the following metals: the Platinum group elements (Platinum, Palladium, Rhodium), Titanium and Arsenic. We applied functional and non functional assays and investigated both innate and adaptive immune systems, in particular, cell proliferation, cytokine production by PBMCs and O*2 production by neutrophils. We obtained the following results: only some Ti compounds (Titanocene, Ti ascorbate and Ti oxalate) show immunotoxicity. Trivalent As compounds (Sodium arsenite and tetraphenyl arsonium chloride) are more immunotoxic than the other investigated As compounds. Genotoxicity of Pt group compounds is in the following order: Pt > Rh > Pd. Immunotoxicity of Pt group compounds is in the following order: Pd > Pt > Rh. Lymphocytes and macrophages show a different reaction of neutrophils to metal toxicity. We can conclude that these studies show that metal immunotoxicity depends on speciation. In general speciation provides additional and often essential information in evaluating metal toxicity. However, there are many difficulties in applying speciation in investigating toxico-kinetic aspects to many metals, mainly due to the lack of information about the existence and significance of species and to the lack of analytical methods for measuring species in biological samples.


Subject(s)
Immune System/drug effects , Metals/toxicity , Arsenic/toxicity , Cells, Cultured , Cytokines/biosynthesis , Humans , Immunity, Innate/drug effects , Lymphocyte Activation/drug effects , Palladium/toxicity , Platinum/toxicity , Rhodium/toxicity , Superoxides/metabolism , Titanium/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...